Pharmanet

	Jeffrey P. McMullen* President and Chief Executive Officer Mr. McMullen’s experience in the drug development industry spans more than 30 years. He spent 13 years with major contract research organizations as Vice President of Business Development and Director of Clinical Research, and 9 years at Sterling Drug in the clinical, regulatory, and drug metabolism areas. Mr. McMullen also has extensive international experience including Europe, Japan, South America, and Asia. Mr. McMullen is focused on the continued growth and global expansion of the organization.
	Mark DiIanni* President, Early Stage Development and Executive Vice President, Strategic Initiatives Mr. Di Ianni was appointed President Early Stage Development in December 2006 and retains his title of Executive Vice President, Strategic Initiatives to which he was appointed in April 2006. Prior to joining PharmaNet as an employee, Mr. Di Ianni provided consulting services to PharmaNet and other clients from February 2005 to March 2006. From September 2002 through January 2005, Mr. Di Ianni was Chief Operating Officer of Synarc, Inc., a medical imaging provider to the clinical trial industry. From May 1996 to December 2001, Mr. Di Ianni was a founding member of and served as Chief Operating Officer and Executive Vice President of SCIREX Corporation, a contract research and clinical site management organization. He has over 25 years experience in the contract research industry.
	John P. Hamill, CPA* Executive Vice President and Chief Financial Officer Mr. Hamill has more than 15 years of experience and has held industry-related senior financial positions with Rhone-Poulenc and Johnson & Johnson. Prior to joining PharmaNet, Mr. Hamill was the Corporate Controller for a major contract research organization. He is currently responsible for PharmaNet financial reporting worldwide.
	Thomas J. Newman, MD* President, Late Stage Development Dr. Newman trained in pediatrics and endocrinology and then served on the faculty at the University of Minnesota Medical School. In 1980, he joined Bristol-Myers Squibb where he worked on the development of a variety of cardiovascular, anti-infective, and diagnostic products and also served as Head of Drug Safety. Prior to joining PharmaNet, Dr. Newman was Vice President of Clinical Research at a major contract research organization.
	Robin C. Sheldrick* Senior Vice President, Human Resources Ms. Sheldrick has worked for more than 20 years in the contract research industry. Her experience includes a combination of clinical research and human resources. As head of human resources, Ms. Sheldrick has worldwide responsibility for employee recruitment and retention, compensation and benefits, employee relations, and training.

* Section 16 Executive Officer

	Johane Boucher-Champagne, DSA President, Anapharm and Executive Vice President, Early Stage Development Ms. Boucher-Champagne was appointed Executive Vice President, Early Clinical Development in March 2006 and was also named president and chief executive officer of Anapharm, Inc., a subsidiary to PharmaNet, in February 2007. Ms. Boucher-Champagne holds an Executive Master's Degree in Administration and a degree in life sciences. She has more than thirty years of experience with health-science research activities, business management and administration.
	Pablo Fernandez, LMS, FFPM Senior Vice President, Medical Affairs, Worldwide Dr. Fernandez joined the pharmaceutical industry in 1979 and has managed international clinical research groups for American Cyanamid, Wyeth-Ayerst, the Wellcome Foundation, and Bayer Biologicals. Originally trained in Internal Medicine and oncology, he has been instrumental in the clinical development and market support of numerous compounds across a wide range of therapeutic areas, including anticancer, infectious diseases, respiratory, and neurology. He is currently responsible for the worldwide medical and scientific affairs group.
	Jeffrey J. Freitag, MD Senior Vice President, PharmaNet Consulting Dr. Freitag has worked in the pharmaceutical industry for more than 20 years in positions including Vice President, New Drug Development at The Liposome Company and, most recently prior to rejoining PharmaNet, as Vice President of Research & Development at Bone Care International. He previously worked at PharmaNet as Senior Vice President of Medical and Scientific Affairs prior to joining Bone Care. Dr. Freitag is board certified in both Internal Medicine and Nephrology and has a strong academic, scientific, and clinical background. He has extensive experience in providing medical and scientific direction and leadership to product development teams. Dr. Freitag has also provided strategic clinical-development consultation to clients in a variety of therapeutic areas, particularly multiple critical care (renal, pulmonary, cardiovascular and infectious disease) therapeutic areas.
	Steven A. George Senior Vice President, Information Technology, Worldwide Mr. George has more than 15 years of information technology experience in the drug development industry. During a career spanning both system development and information technology operations, he has developed core expertise in Internet technologies, systems for accelerating clinical trials, and computer system validation methodologies. At PharmaNet, Mr. George is responsible for corporate infrastructure, desktop support, and the development of advanced information technology, including systems for managing all aspects of clinical trials.
	Dalvir Gill, PhD Senior Executive Vice President and Chief Operating Officer, Late Stage Development Dr. Gill has more than 18 years of experience in international clinical research. In his current position, he has overall responsibility for PharmaNet’s therapeutic divisions, data management, biostatistics, specialized pharmaceutical services and regulatory affairs. Prior to PharmaNet, Dr. Gill spent 9 years in various leadership roles at Rhone-Poulenc Rorer (RPR, now Aventis) in the United States and Europe. During his tenure at RPR, he played a key role in the submission of a number of successful regulatory filings and also held positions in Process Improvement and Corporate Marketing.
	Jack W. Green, PhD Senior Vice President, Biostatistics and Data Management Dr. Green has held senior-level positions for more than 25 years in both the pharmaceutical and contract research industries. He previously was Senior Biostatistician at Merrell-National Labs, Director of Biostatistics at Adria Laboratories, and Senior Vice President of Biostatistics and Data Management at a major contract research organization. In his current position, Dr. Green has established PharmaNet’s biostatistics, statistical programming, data management, and Interactive Voice Response Systems (IVRS) capabilities and has overseen the development of the European data management center.
	Beverly Harrison Senior Vice President, Business Development, Early Stage Development Ms. Harrison has more than 20 years of experience in the clinical development industry, She has held positions of increasing responsibility in business development and operations, with a focus on branded pharmaceuticals in Phase I–IV clinical studies. Prior to joining PharmaNet, she was most recently Vice President and General Manager, the Americas, at MDS Pharma Services. Her previous positions also include President of Trilliant Research,Vice President for Business Development and Chief Business Officer at Premier Research, executive positions at Covance, and clinical research project management for Smith Kline Beckman (now GlaxoSmithKline).
	Gregory M. Hockel, MBA, PhD Executive Vice President, Regulatory Affairs Dr. Hockel has more than 20 years of pharmaceutical, biotechnology, and contract research industry experience, including more than 15 years in regulatory affairs. Throughout his career, Dr. Hockel has been extensively involved in planning, compiling, and submitting numerous NDAs/BLAs and INDs. Additionally, he has led initiatives involving drug safety, GCP auditing, compliance, and clinical trial supply management.
	Ian Holmes, PhD Senior Vice President, Corporate Development Dr. Holmes has more than 30 years of experience in drug development, including 6 years in basic research at Sandoz, 6 years in clinical pharmacology at Merck Sharp & Dohme, and 18 years of contract research experience in global clinical operations and multi-office management. Dr. Holmes is currently based in Zumikon, Switzerland and is responsible for PharmaNet’s European and South African operations and corporate development.
	Mary F. Johnson, PhD Executive Vice President, Biostatistics Dr. Johnson has nearly 30 years of experience with biostatistics in the pharmaceutical industry, including more than 20 years as a Statistical Consultant, advising clients on both statistical and regulatory aspects of clinical development programs. She previously spent 8 years at the FDA as a group leader and statistical reviewer in the Division of Biometrics. At PharmaNet, Dr. Johnson has managed statistical analysis and programming activities for clinical trials in numerous successful NDA/PLA submissions. She has developed statistical analysis plans for studies in most therapeutic areas as well as studies for devices and combination products. Dr. Johnson has authored dozens of publications and presentation for major journals and conferences.
	Michael E. Laird, RPh Senior Vice President, Global Business Development Mr. Laird has more than 20 years of relevant pharmaceutical and contract research industry experience and has held senior-level positions at Smith, Kline & French; Marion Merrell Dow; Proctor & Gamble Pharmaceuticals; and a major contract research organization.
	Sean P. Larkin Senior Executive Vice President, The Americas, Late Stage Development During a pharmaceutical career of more than 20 years, Mr. Larkin has held a wide range of clinical operations and senior-management positions and has managed numerous project teams, including a group of more than 140 employees. Mr. Larkin is responsible for large-scale, multicenter and multinational clinical studies, often involving hundreds of sites and thousands of patients.
	Robert Reekie, FFPM Senior Executive Vice President, Europe and Asia-Pacific, Late Stage Development Dr. Reekie has more than 18 years of industry experience. In positions with Boots Pharmaceuticals, Knoll, DAR, and two major CROs, he provided medical support for commercial groups in both ethical pharmaceuticals and consumer medicines. At PharmaNet, Dr. Reekie provides therapeutic expertise in cardiovascular medicine, rheumatology, depression, analgesia, hospital products, and consumer medicines, including those for dental care, ophthalmology, and cough/cold. In addition, he provides specialized expertise in the design and management of clinical development plans and protocols; and the logistics, feasibility, and implementation of European trials according to the EU Clinical Trial Directive.
	Paul A. Taylor, PhD President, Taylor Technology, Inc. Dr. Taylor has worked in the environmental analytical and bioanalytical industry since 1974 in a variety of positions. He started and built two companies, Enseco and Taylor Technology, Inc. based on state-of-the-art analytical chemistry technologies. As Executive Vice President, Operations of Enseco, he led the integration of the diverse business and analytical systems of three partners. After Corning acquired Enseco in mid-1989, Dr. Taylor founded Taylor Technology, Inc. in 1991 as a mass spectrometry-based bioanalytical lab. Dr. Taylor joined PharmaNet in July, 2004 when PharmaNet acquired Taylor Technology, Inc. His academic training focused on the isolation, identification and biological actions of natural products.